ACE 031

Buy ACE 031 Online

ACE 031 is a soluble activin receptor type IIB (ActRIIB) fusion protein studied for its ability to bind myostatin and other negative regulators of muscle development. Research has focused on muscle mass, strength, and muscle-related disorders.

Product Information

ACE 031 is an engineered protein consisting of the extracellular portion of ActRIIB fused to an IgG1-Fc domain. By binding ligands such as myostatin and activin A, ACE 031 is designed to interfere with signaling pathways that normally limit muscle growth. Human and animal research has demonstrated measurable effects on lean mass and muscle tissue.

How It Works

ACE 031 works by acting as a “decoy receptor” for ActRIIB ligands. By binding myostatin and related signaling molecules before they reach their normal receptors, it can reduce signals that restrict muscle development.

POTENTIAL BENEFITS

1. Muscle Mass Research

ACE 031 has demonstrated increases in lean body mass in controlled research. Human studies have specifically investigated changes in total lean mass and thigh muscle volume following administration.

2. Myostatin Pathway Research

The compound directly targets the ActRIIB signaling pathway involved in myostatin activity. This makes ACE 031 particularly relevant to research involving muscle-growth regulation and inhibition of negative muscle signals.

3. Muscle Strength Research

Animal studies have examined ACE 031 in relation to improvements in skeletal muscle size and contractile performance. More recent non-human-primate research has continued investigating its potential effects on muscle strength.

4. Muscle-Wasting Research

ACE 031 has been investigated in conditions involving impaired muscle development, including Duchenne muscular dystrophy. Research has explored whether blocking myostatin-related signaling can support muscle preservation and function.

Dosage

Human research has investigated single subcutaneous ACE 031 doses ranging from 0.02 to 3 mg/kg in healthy postmenopausal women. The 3 mg/kg group showed measurable increases in lean mass and thigh muscle volume at day 29. These were study doses rather than an established general-use dosing protocol.

Side Effects

Reported research findings include injection-site reactions and changes in vascular-related biomarkers. Because ACE 031 affects multiple ActRIIB ligands rather than myostatin alone, its biological effects extend beyond a single muscle-growth pathway. Clinical development has therefore required careful safety assessment.

References

1. Attie KA, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423.
2. ACE-031 treatment in ambulatory boys with Duchenne muscular dystrophy. Muscle Nerve.
3. ACE-031 increases muscle mass and strength in the common marmoset. PLOS ONE. 2026.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.